ZBH vs JNJ

For growth investors, Zimmer Biomet Holdings, Inc.

(ZBH) is the stronger pick with 7. 2% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 4x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zimmer Biomet Holdings, Inc.

(ZBH) is the cheapest at 23. 4x versus Johnson & Johnson at 39. 0x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +49.

2%, compared to -47. 9% for Zimmer Biomet Holdings, Inc. (ZBH). Over 10 years, the gap is even starker: JNJ returned +136. 8% versus ZBH's -17. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Zimmer Biomet Holdings, Inc. 's 0. 65β — meaning ZBH is approximately 1044% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 59% for Zimmer Biomet Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zimmer Biomet Holdings, Inc.

(ZBH) is pulling ahead at 7. 2% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Zimmer Biomet Holdings, Inc. grew EPS -19. 9% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, ZBH leads at 5. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus 8. 6% for Zimmer Biomet Holdings, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 16. 5% for ZBH. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zimmer Biomet Holdings, Inc.

(ZBH) trades at 9. 8x forward P/E versus 19. 5x for Johnson & Johnson — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZBH: 17. 9% to $97. 90.

All stocks in this comparison pay dividends.

Johnson & Johnson (JNJ) offers the highest yield at 2. 2%, versus 1. 2% for Zimmer Biomet Holdings, Inc. (ZBH).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 8% 10Y return). Both have compounded well over 10 years (JNJ: +136. 8%, ZBH: -17. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.